JP6342495B2 - 新規なアミノピリミジン誘導体 - Google Patents

新規なアミノピリミジン誘導体 Download PDF

Info

Publication number
JP6342495B2
JP6342495B2 JP2016535053A JP2016535053A JP6342495B2 JP 6342495 B2 JP6342495 B2 JP 6342495B2 JP 2016535053 A JP2016535053 A JP 2016535053A JP 2016535053 A JP2016535053 A JP 2016535053A JP 6342495 B2 JP6342495 B2 JP 6342495B2
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
fluoro
halogen
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016535053A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016538313A5 (enExample
JP2016538313A (ja
Inventor
アングスト，ダニエラ
ゲシエール，フランソワ
バルペティ，アナ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2016538313A publication Critical patent/JP2016538313A/ja
Publication of JP2016538313A5 publication Critical patent/JP2016538313A5/ja
Application granted granted Critical
Publication of JP6342495B2 publication Critical patent/JP6342495B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2016535053A 2013-11-29 2014-11-28 新規なアミノピリミジン誘導体 Active JP6342495B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13195081.8 2013-11-29
EP13195081 2013-11-29
PCT/IB2014/066422 WO2015079417A1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018094772A Division JP6667573B2 (ja) 2013-11-29 2018-05-16 新規なアミノピリミジン誘導体

Publications (3)

Publication Number Publication Date
JP2016538313A JP2016538313A (ja) 2016-12-08
JP2016538313A5 JP2016538313A5 (enExample) 2017-10-26
JP6342495B2 true JP6342495B2 (ja) 2018-06-13

Family

ID=49674216

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016535053A Active JP6342495B2 (ja) 2013-11-29 2014-11-28 新規なアミノピリミジン誘導体
JP2018094772A Active JP6667573B2 (ja) 2013-11-29 2018-05-16 新規なアミノピリミジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018094772A Active JP6667573B2 (ja) 2013-11-29 2018-05-16 新規なアミノピリミジン誘導体

Country Status (42)

Country Link
US (7) US9512084B2 (enExample)
EP (5) EP4606377A3 (enExample)
JP (2) JP6342495B2 (enExample)
KR (2) KR102421388B1 (enExample)
CN (2) CN105683181B (enExample)
AP (1) AP2016009158A0 (enExample)
AR (1) AR098549A1 (enExample)
AU (1) AU2014356069B2 (enExample)
BR (1) BR112016010397B1 (enExample)
CA (1) CA2926908C (enExample)
CL (1) CL2016001055A1 (enExample)
CR (1) CR20160244A (enExample)
CU (1) CU24384B1 (enExample)
CY (3) CY1119705T1 (enExample)
DK (3) DK3074386T3 (enExample)
EA (1) EA031218B1 (enExample)
EC (1) ECSP16054826A (enExample)
ES (4) ES3040769T3 (enExample)
FI (2) FI3689865T3 (enExample)
HR (3) HRP20171999T1 (enExample)
HU (3) HUE049794T2 (enExample)
IL (1) IL244943B (enExample)
JO (1) JO3314B1 (enExample)
LT (3) LT3689865T (enExample)
MA (1) MA39055B1 (enExample)
MX (1) MX367911B (enExample)
MY (2) MY191381A (enExample)
NO (1) NO3074386T3 (enExample)
NZ (1) NZ718835A (enExample)
PE (1) PE20160869A1 (enExample)
PH (1) PH12016500791B1 (enExample)
PL (3) PL3299368T3 (enExample)
PT (3) PT3689865T (enExample)
RS (3) RS60251B1 (enExample)
SI (3) SI3299368T1 (enExample)
SV (1) SV2016005206A (enExample)
TN (1) TN2016000128A1 (enExample)
TW (1) TWI652261B (enExample)
UA (1) UA117256C2 (enExample)
UY (1) UY35858A (enExample)
WO (1) WO2015079417A1 (enExample)
ZA (1) ZA201602275B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置
WO2016019300A1 (en) 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
US10577417B2 (en) 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US20180140602A1 (en) * 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
PT3393504T (pt) 2015-12-22 2025-12-30 Novartis Ag Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
US11365252B2 (en) 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
JP7467117B2 (ja) 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
US20200078400A1 (en) 2016-12-03 2020-03-12 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
IL327498A (en) 2017-06-02 2026-05-01 Juno Therapeutics Inc Articles of manufacture and methods for treatment using adoptive cell therapy
CN111050545A (zh) 2017-06-29 2020-04-21 朱诺治疗学股份有限公司 评估与免疫疗法相关的毒性的小鼠模型
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
TWI694995B (zh) 2017-11-06 2020-06-01 美商美國禮來大藥廠 Btk抑制劑化合物
MA51210A (fr) 2017-12-01 2020-10-07 Juno Therapeutics Inc Procédés de dosage et de modulation de cellules génétiquement modifiées
CN108069911A (zh) * 2017-12-14 2018-05-25 中国药科大学 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途
EP3724225A1 (en) 2017-12-15 2020-10-21 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag BCMA chimeric antigen receptors and their uses
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
KR20250119664A (ko) 2018-08-29 2025-08-07 아세르타 파마. 비.브이. 4-｛8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일｝N-(피리딘-2-일)-벤즈아미드의제조 공정
US12473345B2 (en) 2018-11-01 2025-11-18 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
CN119569895A (zh) 2018-11-01 2025-03-07 朱诺治疗学股份有限公司 G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
BR112021009420A2 (pt) 2018-11-16 2021-11-23 Juno Therapeutics Inc Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
EP4427810A3 (en) 2018-11-30 2024-12-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
EA202192103A1 (ru) 2019-01-29 2021-12-15 Джуно Терапьютикс, Инк. Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US12383556B2 (en) * 2019-05-23 2025-08-12 Novartis Ag Methods of treating Sjögren's syndrome using a Bruton's tyrosine kinase inhibitor
FI3972604T3 (fi) * 2019-05-23 2025-09-01 Novartis Ag Brutonin tyrosiinikinaasin estäjä käytettäväksi kroonisen spontaanin urtikarian hoidossa
CN113840821A (zh) * 2019-05-23 2021-12-24 诺华股份有限公司 Btk抑制剂的晶型
WO2020234780A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating asthma using a bruton's tyrosine kinase inhibitor
US12570631B2 (en) 2019-12-23 2026-03-10 Biogen Ma Inc. Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk
IL297147B1 (en) 2020-04-10 2026-05-01 Juno Therapeutics Inc Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen
UY39377A (es) 2020-08-14 2022-03-31 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
CN116209444A (zh) * 2020-08-14 2023-06-02 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物的晶型及其制备方法
EP4284344A1 (en) * 2021-01-26 2023-12-06 Novartis AG Pharmaceutical composition
US20240216330A1 (en) 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
IL310975A (en) 2021-09-03 2024-04-01 Novartis Ag LOU064 for the treatment of multiple sclerosis
CA3239276A1 (en) 2021-12-14 2023-06-22 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
JP2025521543A (ja) 2022-06-22 2025-07-10 ジュノー セラピューティクス インコーポレイテッド Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
EP4565262A2 (en) 2022-08-05 2025-06-11 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
US20260209185A1 (en) * 2022-09-30 2026-07-23 Novartis Ag Synthesis methods and intermediates for the production of remimbrutinib
US20260207667A1 (en) 2022-12-13 2026-07-23 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
CN121752549A (zh) * 2023-09-22 2026-03-27 江苏恒瑞医药股份有限公司 杂芳基类化合物、其制备方法及其在医药上的应用
CN117024354B (zh) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 瑞米布替尼的制备方法
US20250243170A1 (en) * 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity
WO2025210469A2 (en) 2024-04-02 2025-10-09 Novartis Ag Process of preparing remibrutinib substantially free of nitrosamine impurity
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses
WO2026104987A1 (en) 2024-11-13 2026-05-21 Novartis Ag Remibrutinib for use in the treatment of myasthenia gravis
WO2026133229A1 (en) 2024-12-20 2026-06-25 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
EP1373554A2 (en) 2000-10-23 2004-01-02 Bristol-Myers Squibb Company Modulators of bruton's tyronsine kinase, their identification and use
CN1253449C (zh) 2000-11-07 2006-04-26 诺瓦提斯公司 作为蛋白激酶c抑制剂的吲哚基马来酰亚胺衍生物
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
AU2003298607B9 (en) 2002-10-29 2011-08-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR20050084224A (ko) 2002-12-09 2005-08-26 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 야누스 티로신 키나제 3을 선택적으로 저해하는 방법
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
EP1628967B1 (en) 2003-05-19 2014-04-09 Irm Llc Immunosuppressant compounds and compositions
ES2389203T3 (es) 2004-01-12 2012-10-24 Ym Biosciences Australia Pty Ltd Inhibidores de quinasa selectivos
AU2006223409B2 (en) 2005-03-10 2011-07-21 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
DK2134374T3 (en) 2007-03-14 2014-02-24 Bionsil S R L In Liquidazione BTK-INHIBITORS FOR USE IN PROCESSING chemotherapeutic agent RESISTANT TUMORS Epithelial
CA2723237A1 (en) 2008-05-06 2009-11-12 Peter A. Blomgren Substituted amides, method of making, and use as btk inhibitors
PL2300459T3 (pl) 2008-07-02 2013-10-31 Hoffmann La Roche Nowe fenylopirazynony jako inhibitory kinazy
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
US20100261776A1 (en) 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
ES2513915T3 (es) 2009-04-24 2014-10-27 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
ES2562959T3 (es) * 2010-02-26 2016-03-09 Evotec International Gmbh Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
EP2694486B1 (en) 2011-04-01 2018-01-10 University of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
DK2710007T3 (da) 2011-05-17 2020-01-27 Principia Biopharma Inc Kinasehæmmere
US9073947B2 (en) 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
WO2013003629A2 (en) 2011-06-28 2013-01-03 Pharmacyclics, Inc. Methods and compositions for inhibition of bone resorption
ES2548414T3 (es) 2011-07-08 2015-10-16 Novartis Ag Novedosos derivados de pirrolo pirimidina
EP2742138B1 (en) 2011-08-09 2020-06-24 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
US20140303191A1 (en) 2011-10-19 2014-10-09 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
MX2014006674A (es) 2011-12-09 2014-09-04 Hoffmann La Roche Inhibidores de tirosina cinasa de bruton.
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2013173518A1 (en) 2012-05-16 2013-11-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CN104603124B (zh) 2012-08-10 2018-04-17 勃林格殷格翰国际有限公司 用作布鲁顿酪氨酸激酶(btk)抑制剂的杂芳族化合物
KR102194611B1 (ko) 2012-10-04 2020-12-23 유니버시티 오브 유타 리서치 파운데이션 티로신 수용체 키나아제 btk 억제제로서 치환된 n-(3-(피리미딘-4-일)페닐)아크릴아미드 유사체
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Also Published As

Publication number Publication date
PL3074386T3 (pl) 2018-03-30
CA2926908A1 (en) 2015-06-04
US10457647B2 (en) 2019-10-29
CN105683181B (zh) 2019-04-23
FI3689865T3 (fi) 2023-06-12
HUE037588T2 (hu) 2018-09-28
PT3299368T (pt) 2020-05-28
EP4219478B1 (en) 2025-06-11
LT3689865T (lt) 2023-07-10
BR112016010397A8 (pt) 2020-04-22
EA031218B1 (ru) 2018-12-28
CR20160244A (es) 2016-07-29
PH12016500791A1 (en) 2016-06-13
EP3074386A1 (en) 2016-10-05
CA2926908C (en) 2021-10-26
HRP20171999T1 (hr) 2018-02-09
AU2014356069A1 (en) 2016-05-05
CN110172056A (zh) 2019-08-27
SI3299368T1 (sl) 2020-07-31
MA39055A1 (fr) 2018-02-28
MX2016006908A (es) 2016-08-17
EP3299368B1 (en) 2020-02-26
HRP20200775T1 (hr) 2020-07-24
EP4219478A1 (en) 2023-08-02
AU2014356069B2 (en) 2017-06-15
ES2655527T3 (es) 2018-02-20
EP4606377A2 (en) 2025-08-27
LT3074386T (lt) 2017-12-27
UY35858A (es) 2015-06-30
PT3074386T (pt) 2017-11-15
CN110172056B (zh) 2022-04-19
MY179059A (en) 2020-10-26
HK1223368A1 (en) 2017-07-28
TW201609666A (zh) 2016-03-16
EP4606377A3 (en) 2025-11-26
AR098549A1 (es) 2016-06-01
CL2016001055A1 (es) 2016-10-28
SI3689865T1 (sl) 2023-07-31
JP2018141005A (ja) 2018-09-13
RS64275B1 (sr) 2023-07-31
CY1126056T1 (el) 2023-11-15
NZ718835A (en) 2021-12-24
KR102421388B1 (ko) 2022-07-18
AP2016009158A0 (en) 2016-04-30
US20200010426A1 (en) 2020-01-09
US11180460B2 (en) 2021-11-23
US20260132113A1 (en) 2026-05-14
JP2016538313A (ja) 2016-12-08
JP6667573B2 (ja) 2020-03-18
MA39055B1 (fr) 2018-10-31
KR20160088877A (ko) 2016-07-26
UA117256C2 (uk) 2018-07-10
US20180251432A1 (en) 2018-09-06
CN105683181A (zh) 2016-06-15
PT3689865T (pt) 2023-06-16
IL244943B (en) 2020-04-30
US20150152068A1 (en) 2015-06-04
LT3299368T (lt) 2020-05-25
ES3040769T3 (en) 2025-11-04
CY1119705T1 (el) 2018-06-27
HK1252317A1 (en) 2019-05-24
RS60251B1 (sr) 2020-06-30
ECSP16054826A (es) 2017-10-31
TWI652261B (zh) 2019-03-01
CY1122924T1 (el) 2021-10-29
IL244943A0 (en) 2016-05-31
EP3689865A1 (en) 2020-08-05
JO3314B1 (ar) 2019-03-13
RS56657B1 (sr) 2018-03-30
SI3074386T1 (en) 2018-02-28
FIC20265019I1 (fi) 2026-08-07
US11673868B2 (en) 2023-06-13
MY191381A (en) 2022-06-22
EP3074386B1 (en) 2017-10-11
NO3074386T3 (enExample) 2018-03-10
US20160235746A1 (en) 2016-08-18
HUE062248T2 (hu) 2023-10-28
ZA201602275B (en) 2017-08-30
ES2791525T3 (es) 2020-11-04
CU24384B1 (es) 2019-03-04
PL3689865T3 (pl) 2023-07-31
HRP20230585T1 (hr) 2023-09-01
EA201691125A1 (ru) 2016-09-30
PE20160869A1 (es) 2016-09-08
DK3299368T3 (da) 2020-05-25
DK3074386T3 (en) 2018-01-22
DK3689865T3 (en) 2023-06-19
MX367911B (es) 2019-09-11
KR20220044370A (ko) 2022-04-07
WO2015079417A1 (en) 2015-06-04
PL3299368T3 (pl) 2020-08-10
CU20160078A7 (es) 2016-09-30
US9512084B2 (en) 2016-12-06
KR102380539B1 (ko) 2022-03-29
US20220041561A1 (en) 2022-02-10
SV2016005206A (es) 2016-11-21
PH12016500791B1 (en) 2016-06-13
HUE049794T2 (hu) 2020-10-28
TN2016000128A1 (en) 2017-10-06
US20230312483A1 (en) 2023-10-05
EP3689865B1 (en) 2023-03-29
ES2947770T3 (es) 2023-08-18
EP3299368A1 (en) 2018-03-28
BR112016010397B1 (pt) 2023-04-11

Similar Documents

Publication Publication Date Title
US11673868B2 (en) Amino pyrimidine derivatives
HK40127042A (en) Novel amino pyrimidine derivatives
HK40089302B (en) Method of preparing amino pyrimidine derivatives
HK40024076A (en) Novel amino pyrimidine derivatives
HK40024076B (en) Novel amino pyrimidine derivatives
HK1252317B (en) Novel amino pyrimidine derivatives
HK1223368B (en) Novel amino pyrimidine derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170913

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180419

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180424

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180516

R150 Certificate of patent or registration of utility model

Ref document number: 6342495

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250